SCHEMBL6345016

SCHEMBL6345016

CCOC(=O)c1sc(Br)c(Br)c1CBr

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
KMT2A Q03164 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MC4R P32245 1/20 0.41
ALDH1A1 P00352 6/20 0.41
CYP1A2 P05177 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
HPGD P15428 3/20 0.40
PLK1 P53350 1/20 0.38
DHODH Q02127 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345019 0.87 KMT2A (0.41) MAPTKMT2ANPC1RAB9AGAA
SCHEMBL1974662 0.83 KMT2A (0.46) MAPTKMT2AGAAHSD17B10ALDH1A1
SCHEMBL21612061 0.82 MAPT (0.46) MAPTKMT2ANPC1RAB9AGAA
SCHEMBL5271074 0.81 MAPT (0.53) MAPTKMT2ANPC1RAB9AGAA
SCHEMBL5727280 0.78 MAPT (0.42) MAPTKMT2ANPC1RAB9AGAA
SCHEMBL20598163 0.78 MAPT (0.42) MAPTKMT2ANPC1RAB9AGAA
SCHEMBL9118445 0.77 LMNA (0.48) MAPTKMT2ANPC1RAB9AGAA
SCHEMBL29980612 0.76 KMT2A (0.55) MAPTKMT2ANPC1RAB9AGAA
SCHEMBL12483037 0.75 MAPT (0.50) MAPTKMT2ANPC1RAB9AGAA
SCHEMBL28907995 0.72 MAPT (0.65) MAPTKMT2ANPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256124-A1 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto NEUROCRINE BIOSCIENCES, INC. (US) 2005-11-17 US disclosed
WO-2005103039-A1 2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES AS MELANIN-CONCENTRATING HORMONE RECEPTOR AN TAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256124-A1 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto MCHR1, MCHR2, MC1R MAPT 3869/4885KMT2A 1469/4885NPC1 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.